Mechanism of the Cardiotoxic Actions of Terfenadine

JAMA: The Journal of the American Medical Association

Volumn 269, Issue 12, 1993, Pages 1532-1536

  Woosley, Raymond L ^a   Chen, Yiwang ^a   Freiman, Joel P ^b   Gillis, Richard A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DISOPYRAMIDE; DRUG METABOLITE; HALOPERIDOL; KETOCONAZOLE; PENTAMIDINE; PROBUCOL; PROCAINAMIDE; QUINIDINE; SOTALOL; TERFENADINE; THIORIDAZINE;

ADULT; AGED; ANIMAL CELL; ARTICLE; CARDIOTOXICITY; CAT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG METABOLISM; DRUG POTENCY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART REPOLARIZATION; HUMAN; MALE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; RISK FACTOR; TORSADE DES POINTES;

ADOLESCENT; ADULT; AGED; ANIMAL; CATS; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART; HUMAN; IN VITRO; MALE; MIDDLE AGE; MYOCARDIUM; POTASSIUM CHANNELS; QUINIDINE; TERFENADINE; TORSADES DE POINTES; VECTORCARDIOGRAPHY;

EID: 0027474601     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1993.03500120070028     Document Type: Article

References (28)

1. Simonsen LL. What are pharmacists dispensing most often? Pharmacy Times. April 1992:47-65.
2. 1991 National Prescription Audit. Plymouth Meeting, Pa: IMS America Ltd; 1992.
3. Coutant JE, Westmark PA, Nardella PA, Walter SM, Okerholm RA. Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1991;570:139-148.
4. Yun C, Okerholm RA, Guengerich FP. Oxidation of the anithistaminic drug terfenadine in human microsomes: role of cytochrome P450 3A4 in N-dealkylation C-hydroxylation. Drug Metab Dispos. In press.
5. Sorkin EM, Heel RC. Terfenadine: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1985;29:34-56.
6. Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ. 1989;298:325.
7. MacConnell TJ, Stanners AJ. Torsades de pointes complicating treatment with terfenadine. BMJ. 1991;302:1469.
8. Wiley JF, Gelber ML, Henretig FM, Wiley CC, Sandhu S, Loiselle J. Cardiotoxic effects of astemizole overdose in children. J Pediatr. 1992;120:799-802.
9. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990;264:2788-2790.
10. Brown MW, Maldonado AL, Meredith CG, Speeg KV Jr. Effect of ketoconazole on hepatic oxidative metabolism. Clin Pharmacol Ther. 1985; 37:290-297.
11. Marion Merrell Dow. Seldane. In: Physician’s Desk Reference. Montvale, NJ: Medical Economics Data; 1992:1349-1350.
12. Important Drug Warning. Cincinnati, Ohio: Marion Merrell Dow Inc; August 6, 1990.
13. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088-1093.
14. January CT, Riddle JM. Early after-depolarizations: mechanism of induction and block. Circ Res. 1989;64:977-990.
15. Cranefield PF, Aronson RS. Torsades de pointes and early afterdepolarizations. Cardiovasc Drug Ther. 1991;5:531-538.
16. Zehender M, Hohnloser SH, Just H. QT-Interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drug Ther. 1991;5:515-530.
17. Silver LH, Houser SR. Transmembrane potassium fluxes in isolated feline ventricular myocytes. Am J Physiol. 1985;248:H614-H621.
18. Follmer CH, Colatsky TJ. Block of delayed rectifier potassium current, Ik, by flecainide and E-4031 in cat ventricular myocytes. Circulation. 1990;82: 289-293.
19. Kleiman RB, Houser SR. Outward currents in normal and hypertrophied feline ventricular myocytes. Am J Physiol. 1989;256:H1450-H1461.
20. Follmer CH, Cullinan CA, Colatsky TJ. Amiodarone: delayed rectifier block selectivity in cat ventricular myocytes. Circulation. 1990;82(suppl III):11.
21. Faich GA. Adverse-drug-reaction reporting. N Engl J Med. 1986;14:1589.
22. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 1988;31: 115-172.
23. Minardo JD, Heger JJ, Miles WM, Zipes DP, Prystowsky EN. Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med. 1990;319:257-262.
24. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther. 1992;3:231-238.
25. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269:1513-1518.
26. May DG, Black CM, Olsen NJ, et al. Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin. Clin Pharmacol Ther. 1990;48:268-295.
27. Guengerich FP, Kim DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogen. 1992;11:2275-2279.
28. Goldberg RJ, Bengtson J, Chen Z, Anderson KM, Locati E, Levy D. Duration of the QT interval and total cardiovascular mortality in healthy persons (the Framingham Heart Study experience). Am J Cardiol. 1991;67:55-58.